{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:52:03Z","timestamp":1780491123621,"version":"3.54.1"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Ottawa Hospital Academic Medical Organization","award":["TOH-25-014"],"award-info":[{"award-number":["TOH-25-014"]}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00c3\u00a9 \u00e2\u20ac\u201c Universit\u00c3\u00a4tsmedizin Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hallucinogen use for both recreational and medical purposes is rapidly increasing globally, raising concerns about potential adverse effects. This study examined the risk of incident mania or bipolar disorder (BD) diagnosis associated with having an emergency department (ED) visit or hospitalization involving hallucinogens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We used a population-based cohort study of all individuals aged 14\u201365 years with no baseline history of BD and registered in the Ontario Health Insurance Plan in Ontario, Canada, between 2008\u20132022. Incident mania (primary outcome) and incident BD (secondary outcome) were compared between individuals with acute care (an ED visit or hospitalization) involving hallucinogens and the general population using overlap propensity score weighted Cox proportional hazard models. Models were adjusted for age, sex, rural residence, income quintile, recent documentation of homelessness, and healthcare encounters for mental health or other substance use in the past five years. The study included 9,311,844 individuals of which 7,285 (0.08%) had acute care involving hallucinogens. Within 3-years of acute care involving hallucinogens, 1.43% (n\u2009=\u2009104) of individuals had an incident episode of mania requiring acute care compared to 0.06% (n\u2009=\u200941) of individuals in the age-sex matched general population, a 25-fold increase in risk. After weighting, acute care for hallucinogens was associated with a 6-fold (weighted Hazard Ratio [HR] 5.97, 95% CI 3.29, 10.82) increase in risk of incident mania relative to individuals without hallucinogen acute care who had otherwise similar demographic and mental health histories. Associated increases were also observed for risk of an incident diagnosis of BD (HR 3.75 95%CI 2.49, 5.65, absolute proportion 2.50% versus 0.11%). The main limitation of the study is the risk associated with the exposure examined in this study may not generalize to the majority of people who use hallucinogens who do not require acute care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest the need for ongoing caution regarding hallucinogen use in individuals at risk of bipolar disorder. They also have potential implications for clinical practice, research, and public health policy, including substance regulation and targeted education for high-risk groups in the context of rising hallucinogen use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004805","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:21:45Z","timestamp":1764699705000},"page":"e1004805","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hospital-based care for hallucinogens and risk of mania and bipolar disorder: A population-based cohort study"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8038-300X","authenticated-orcid":true,"given":"Daniel T.","family":"Myran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2016-3232","authenticated-orcid":true,"given":"Rachael","family":"MacDonald-Spracklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-4071","authenticated-orcid":true,"given":"Jess G.","family":"Fiedorowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-4794","authenticated-orcid":true,"given":"Tyler S.","family":"Kaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":true,"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"12","key":"pmed.1004805.ref001","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/add.15987","article-title":"Adolescent and adult time trends in US hallucinogen use, 2002\u201319: any use, and use of ecstasy, LSD and PCP","volume":"117","author":"O Livne","year":"2022","journal-title":"Addiction"},{"key":"pmed.1004805.ref002","volume-title":"Canadian alcohol and drugs survey (CADS): 2019 detailed tables","author":"Health Canada","year":"2023"},{"key":"pmed.1004805.ref003","volume-title":"Canadian alcohol and drugs survey (CADS): summary of results for 2019","author":"Health Canada","year":"2023"},{"key":"pmed.1004805.ref004","volume-title":"Monitoring the future panel study annual report: national data on substance use among adults ages 19 to 65, 1976-2023","author":"ME Patrick","year":"2024"},{"issue":"5","key":"pmed.1004805.ref005","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/add.16432","article-title":"Trends in hallucinogen-associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022","volume":"119","author":"N Garel","year":"2024","journal-title":"Addiction"},{"key":"pmed.1004805.ref006","article-title":"Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder","author":"DT Myran","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"pmed.1004805.ref007","volume-title":"Drug and alcohol use in Canada: general population (Ages 15)","author":"Health Canada","year":"2025"},{"issue":"3","key":"pmed.1004805.ref008","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41380-024-02800-5","article-title":"Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies","volume":"30","author":"M Sab\u00e9","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"7","key":"pmed.1004805.ref009","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bdi.13095","article-title":"An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: a case report","volume":"23","author":"H Hendin","year":"2021","journal-title":"Bipolar Disord"},{"issue":"12","key":"pmed.1004805.ref010","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1176\/appi.ajp.22010073","article-title":"A case of prolonged mania, psychosis, and severe depression after psilocybin use: implications of increased psychedelic drug availability","volume":"179","author":"G Barber","year":"2022","journal-title":"Am J Psychiatry"},{"key":"pmed.1004805.ref011","doi-asserted-by":"crossref","first-page":"1221131","DOI":"10.3389\/fpsyt.2023.1221131","article-title":"Manic episode following psilocybin use in a man with bipolar II disorder: a case report","volume":"14","author":"HJ Halim","year":"2023","journal-title":"Front Psychiatry"},{"issue":"3","key":"pmed.1004805.ref012","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ajad.12209","article-title":"Mania following use of ibogaine: a case series","volume":"24","author":"CJ Marta","year":"2015","journal-title":"Am J Addict"},{"key":"pmed.1004805.ref013","first-page":"100240","article-title":"Evaluating the risk of psilocybin for the treatment of bipolar depression: a review of the research literature and published case studies","volume":"6","author":"DE Gard","year":"2021","journal-title":"J Affect Disord Rep"},{"key":"pmed.1004805.ref014","first-page":"1","article-title":"Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports","author":"B Yildirim","year":"2024","journal-title":"Psychol Med"},{"issue":"8","key":"pmed.1004805.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063972","article-title":"Psychedelics and mental health: a population study","volume":"8","author":"TS Krebs","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"pmed.1004805.ref016","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/jamapsychiatry.2024.0047","article-title":"Adolescent psychedelic use and psychotic or manic symptoms","volume":"81","author":"O Simonsson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"pmed.1004805.ref017","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291725000716","article-title":"Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms","volume":"55","author":"O Simonsson","year":"2025","journal-title":"Psychol Med"},{"issue":"6","key":"pmed.1004805.ref018","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1017\/S0033291704003307","article-title":"Incidence and distribution of first-episode mania by age: results from a 35-year study","volume":"35","author":"N Kennedy","year":"2005","journal-title":"Psychol Med"},{"key":"pmed.1004805.ref019","volume-title":"Controlled drugs and substances act","author":"Government of Canada","year":"1996"},{"key":"pmed.1004805.ref020","unstructured":"Government of Canada. Changes to special access program (SAP). Accessed 2025 July 10. https:\/\/www.canada.ca\/en\/news\/archive\/2013\/10\/changes-special-access-program-sap-.html?utm_source=chatgpt.com"},{"key":"pmed.1004805.ref021","unstructured":"Health Canada. Application form for an exemption to use a controlled substance for clinical studies. 2023. Accessed 2025 July 10. https:\/\/www.canada.ca\/en\/health-canada\/services\/health-concerns\/controlled-substances-precursor-chemicals\/exemptions\/application-form-exemption-use-controlled-substance-clinical-studies.html?utm_source=chatgpt.com"},{"issue":"1","key":"pmed.1004805.ref022","article-title":"Regulations amending certain regulations relating to restricted drugs (special access program)","volume":"156","author":"Canada Government of","year":"2022","journal-title":"Canada Gazette, Part II"},{"key":"pmed.1004805.ref023","unstructured":"Health Canada. Special access program for drugs: guidance document for industry and practitioners. Health Canada. 2022. Accessed 2025 July 10. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/special-access\/drugs\/guidance.html?utm_source=chatgpt.com#a61"},{"key":"pmed.1004805.ref024","volume-title":"Early psychosis intervention program standards","author":"Ministry of Health and Long-Term Care","year":"2011"},{"issue":"8","key":"pmed.1004805.ref025","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/jamapsychiatry.2023.1256","article-title":"Cannabis use disorder and subsequent risk of psychotic and nonpsychotic unipolar depression and bipolar disorder","volume":"80","author":"OH Jefsen","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"pmed.1004805.ref026","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/ipj.ipj_43_23","article-title":"Cannabis use and its relationship with bipolar disorder: a systematic review and meta-analysis","volume":"32","author":"G Maggu","year":"2023","journal-title":"Indian Psychiatry Journal"},{"issue":"6","key":"pmed.1004805.ref027","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1600-0447.2011.01747.x","article-title":"Validity of bipolar disorder hospital discharge diagnoses: file review and multiple register linkage in Sweden","volume":"124","author":"C Sellgren","year":"2011","journal-title":"Acta Psychiatr Scand"},{"key":"pmed.1004805.ref028","doi-asserted-by":"crossref","first-page":"111430","DOI":"10.1016\/j.jclinepi.2024.111430","article-title":"Identification of homelessness using health administrative data in Ontario, Canada following a national coding mandate: a validation study","volume":"172","author":"L Richard","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"pmed.1004805.ref029","unstructured":"MHASEF Research Team. Mental Health and Addictions System Performance in Ontario: A Baseline Scorecard. 2018. https:\/\/www.ices.on.ca\/publications\/research-reports\/mental-health-and-addictions-system-performance-in-ontario-a-baseline-scorecard\/"},{"issue":"3","key":"pmed.1004805.ref030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1377\/hlthaff.2017.1150","article-title":"Accumulation of chronic conditions at the time of death increased in Ontario from 1994 to 2013","volume":"37","author":"L Rosella","year":"2018","journal-title":"Health Aff"},{"issue":"6","key":"pmed.1004805.ref031","doi-asserted-by":"crossref","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"PC Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"issue":"10","key":"pmed.1004805.ref032","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pds.5639","article-title":"Differences in target estimands between different propensity score-based weights","volume":"32","author":"PC Austin","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"23","key":"pmed.1004805.ref033","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"LE Thomas","year":"2020","journal-title":"JAMA"},{"issue":"30","key":"pmed.1004805.ref034","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"PC Austin","year":"2016","journal-title":"Stat Med"},{"issue":"11","key":"pmed.1004805.ref035","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jamapsychiatry.2023.3582","article-title":"Transition to Schizophrenia Spectrum Disorder Following Emergency Department Visits Due to Substance Use With and Without Psychosis","volume":"80","author":"DT Myran","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"pmed.1004805.ref036","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/psymed.2024.0032","article-title":"Psilocybin-assisted psychotherapy for treatment-resistant depression in bipolar II disorder","volume":"3","author":"S Meshkat","year":"2025","journal-title":"Psychedelic Med (New Rochelle)"},{"issue":"6","key":"pmed.1004805.ref037","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial","volume":"81","author":"ST Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"pmed.1004805.ref038","article-title":"Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis","volume":"386","author":"T-W Hsu","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"pmed.1004805.ref039","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40345-022-00265-5","article-title":"Psychedelics in the treatment of unipolar and bipolar depression","volume":"10","author":"OG Bosch","year":"2022","journal-title":"Int J Bipolar Disord"},{"issue":"5","key":"pmed.1004805.ref040","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/01.jcp.0000237950.65517.be","article-title":"Manic\/hypomanic switch during acute antidepressant treatment for unipolar depression","volume":"26","author":"K Wada","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"pmed.1004805.ref041","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.2014.13111501","article-title":"The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer","volume":"171","author":"A Viktorin","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"45","key":"pmed.1004805.ref042","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1523\/JNEUROSCI.1121-22.2022","article-title":"Psychedelics and neural plasticity: therapeutic implications","volume":"42","author":"SF Grieco","year":"2022","journal-title":"J Neurosci"},{"key":"pmed.1004805.ref043","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neubiorev.2019.12.001","article-title":"Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms","volume":"108","author":"RG dos Santos","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"pmed.1004805.ref044","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jad.2024.01.197","article-title":"Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom","volume":"351","author":"L Honk","year":"2024","journal-title":"J Affect Disord"},{"key":"pmed.1004805.ref045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jad.2023.01.073","article-title":"Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics","volume":"326","author":"O Simonsson","year":"2023","journal-title":"J Affect Disord"},{"issue":"4","key":"pmed.1004805.ref046","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2853","article-title":"Psilocybin dispensaries and online health claims in Canada","volume":"8","author":"J Matsukubo","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"pmed.1004805.ref047","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/dar.12263","article-title":"Polysubstance use, mental health and high-risk behaviours: results from the 2012 Global drug survey","volume":"34","author":"KI Morley","year":"2015","journal-title":"Drug Alcohol Rev"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:21:52Z","timestamp":1764699712000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004805"}},"subtitle":[],"editor":[{"given":"Nicolas","family":"Garel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004805","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]}}}